SEC Tracker
Get the app
Person · CIK 1871145

Jason O'Byrne

EVP & Chief Financial Officer at Vir Biotechnology; CHIEF FINANCIAL OFFICER at Olema Pharmaceuticals

Earlier: Caribou Biosciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$69K
Noticed on Form 144$1.2M
Bought on Form 4$0
Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Olema Pharmaceuticals OLMAStock Option (Right to Buy)
exercise $10.56, expires Aug 31, 2036, into Common Stock
Directly650,000Sep 1, 2026 · Filing · EDGAR
Vir Biotechnology VIRCommon StockDirectly160,115Mar 20, 2026 · Filing · EDGAR
Vir Biotechnology VIRCommon StockSee Footnote2,500Mar 20, 2026 · Filing · EDGAR
Vir Biotechnology VIRStock Option (Right to Buy)
exercise $7.56, expires Feb 21, 2036, into Common Stock
Directly110,000Feb 22, 2026 · Filing · EDGAR
Caribou BiosciencesCommon StockDirectly59,224Feb 20, 2024 · Filing · EDGAR
Caribou BiosciencesOption to purchase Common Stock
exercise $6.81, expires Feb 19, 2034, into Common Stock
Directly153,000Feb 20, 2024 · Filing · EDGAR

Sold and noticed by quarter

Jason O'Byrne: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$1.2M$0Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $38K noticed on Form 144Q4 2025: $38K sold on Form 4Q1 2026: $31K noticed on Form 144Q1 2026: $31K sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $1.2M noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026—$1.2M
Q1 2026$31K$31K
Q4 2025$38K$38K

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Vir Biotechnology VIR · Fidelity Brokerage Services · No 10b5-1 plan stated · 8 notices
Sep 17, 202619,357 · ~$213KSep 17, 2026Not sold yetFiling · EDGAR
Sep 9, 202628,333 · ~$315KSep 9, 2026Not sold yetFiling · EDGAR
Aug 25, 202623,148 · ~$243KAug 25, 2026Not sold yetFiling · EDGAR
Aug 24, 202614,352 · ~$142KAug 24, 2026Not sold yetFiling · EDGAR
Aug 21, 202625,000 · ~$245KAug 21, 2026Not sold yetFiling · EDGAR
Feb 24, 20261,634 · ~$16KFeb 24, 2026Sold as noticed Sold 1,634 at $9.53 on Feb 24 · $16K Form 4Filing · EDGAR
Feb 23, 20262,089 · ~$16KFeb 23, 2026Sold as noticed Sold 2,089 at $7.45 on Feb 23 · $16K Form 4Filing · EDGAR
Nov 17, 20256,799 · ~$38KNov 17, 2025Sold as noticed Sold 6,799 at $5.56 on Nov 17 · $38K Form 4Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Vir Biotechnology VIR EVP & Chief Financial Officer · filings 2024 to 2026 · sold $69K · $1.2M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Mar 20, 2026Other acquisition or disposition (see the filing)−2,500160,115 directFiling · EDGAR
Mar 20, 2026Other acquisition or disposition (see the filing)+2,5002,500
See Footnote
Filing · EDGAR
Feb 24, 2026Sale under a 10b5-1 plan−1,634$9.53$16K162,615 directFiling · EDGAR
Feb 23, 2026Sale under a 10b5-1 plan−2,089$7.45$16K164,249 directFiling · EDGAR
Feb 22, 2026Grant or award from the company+55,000166,338 directFiling · EDGAR
Feb 22, 2026Grant or award from the company
Stock Option (Right to Buy)
+110,000110,000 directFiling · EDGAR
Nov 17, 2025Sale under a 10b5-1 plan−6,799$5.56$38K110,701 directFiling · EDGAR
Feb 22, 2025Grant or award from the company+40,000115,000 directFiling · EDGAR
Feb 22, 2025Grant or award from the company
Stock Option (Right to Buy)
+80,00080,000 directFiling · EDGAR
Nov 15, 2024Grant or award from the company+75,00075,000 directFiling · EDGAR
Nov 15, 2024Grant or award from the company
Stock Option (Right to Buy)
+150,000150,000 directFiling · EDGAR

Olema Pharmaceuticals OLMA Chief financial officer · filings 2026 to 2026

DateTransactionSharesPriceValueHeld afterSource
Sep 1, 2026Grant or award from the company
Stock Option (Right to Buy)
+650,000650,000 directFiling · EDGAR

Caribou Biosciences Chief Financial Officer · filings 2021 to 2024

DateTransactionSharesPriceValueHeld afterSource
Feb 20, 2024Grant or award from the company+33,00059,224 directFiling · EDGAR
Feb 20, 2024Grant or award from the company
Option to purchase Common Stock
+153,000153,000 directFiling · EDGAR
Feb 21, 2023Grant or award from the company
Option to purchase Common Stock
+131,000131,000 directFiling · EDGAR
Feb 8, 2022Option or RSU exercised or converted+24,336$4.11$100K24,336 directFiling · EDGAR
Feb 8, 2022Option or RSU exercised or converted
Option to purchase Common Stock
−24,336412,865 directFiling · EDGAR
Dec 20, 2021Grant or award from the company
Option to purchase Common Stock
+147,000147,000 directFiling · EDGAR
All 22 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 17, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Sep 9, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Sep 2, 2026Form 4Olema Pharmaceuticals OLMAFiling · EDGAR
Aug 25, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Aug 24, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Aug 21, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Aug 13, 2026Form 3Olema Pharmaceuticals OLMAFiling · EDGAR
Mar 23, 2026Form 4Vir Biotechnology VIRFiling · EDGAR
Feb 26, 2026Form 4Vir Biotechnology VIRFiling · EDGAR
Feb 24, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Feb 24, 2026Form 4Vir Biotechnology VIRFiling · EDGAR
Feb 23, 2026Form 144Vir Biotechnology VIRFiling · EDGAR
Nov 18, 2025Form 4Vir Biotechnology VIRFiling · EDGAR
Nov 17, 2025Form 144Vir Biotechnology VIRFiling · EDGAR
Feb 25, 2025Form 4Vir Biotechnology VIRFiling · EDGAR
Nov 18, 2024Form 4Vir Biotechnology VIRFiling · EDGAR
Oct 3, 2024Form 3Vir Biotechnology VIRFiling · EDGAR
Feb 22, 2024Form 4Caribou BiosciencesFiling · EDGAR
Feb 23, 2023Form 4Caribou BiosciencesFiling · EDGAR
Feb 8, 2022Form 4Caribou BiosciencesFiling · EDGAR
Dec 21, 2021Form 4Caribou BiosciencesFiling · EDGAR
Jul 22, 2021Form 3Caribou BiosciencesFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.